Literature DB >> 15866260

Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.

Antonio Fernández-Nebro1, Eva Tomero, Vera Ortiz-Santamaría, María Carmen Castro, Alejandro Olivé, Manuel de Haro, Rosa García Portales, Rosa García-Vicuña, María Victoria González-Mari, Armando Laffón, Rosario García-Vicuña.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15866260     DOI： 10.1016/j.amjmed.2005.01.028

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  18 in total

1.  Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease.

Authors:  M Iizuka; S Konno; Y Horie; H Itou; K Shindo; S Watanabe
Journal:  Gut       Date:  2006-05       Impact factor: 23.059

Review 2.  Treatment of chronic inflammatory diseases with biologic agents: opportunities and risks for the elderly.

Authors:  Alejandro Diaz-Borjon; Cornelia M Weyand; Jörg J Goronzy
Journal:  Exp Gerontol       Date:  2006-11-27       Impact factor: 4.032

3.  Anti-TNF-alpha for treatment of amyloidosis associated with Crohn's disease.

Authors:  A Fernández-Nebro; I Ureña; M V Irigoyen; R García-Vicuña
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

Review 4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

5.  Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease.

Authors:  Keiichi Sumida; Miklos Z Molnar; Praveen K Potukuchi; Fatima Hassan; Fridtjof Thomas; Kunihiro Yamagata; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Kidney Int       Date:  2018-03-02       Impact factor: 10.612

6.  Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.

Authors:  Tadashi Nakamura; Syu-ichi Higashi; Kunihiko Tomoda; Michishi Tsukano; Masahiro Shono
Journal:  Clin Rheumatol       Date:  2010-05-05       Impact factor: 2.980

Review 7.  Gastrointestinal and Hepatic Disease in Rheumatoid Arthritis.

Authors:  Ethan Craig; Laura C Cappelli
Journal:  Rheum Dis Clin North Am       Date:  2018-02       Impact factor: 2.670

8.  The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis.

Authors:  Soner Senel; Bunyamin Kisacik; Yunus Ugan; Timucin Kasifoglu; Ercan Tunc; Veli Cobankara
Journal:  Clin Rheumatol       Date:  2011-05-28       Impact factor: 2.980

Review 9.  Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice.

Authors:  Cecilia Mercieca; Irene E van der Horst-Bruinsma; Andrew A Borg
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

10.  [Renal manifestations in rheumatic diseases].

Authors:  K de Groot
Journal:  Internist (Berl)       Date:  2007-08       Impact factor: 0.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.